

Supporting Information
for
A convenient route to symmetrically and unsymmetrically
substituted 3,5-diaryl-2,4,6-trimethylpyridines via Suzuki–
Miyaura cross-coupling reaction

Dariusz Błachut^{*1}, Joanna Szawkało², Zbigniew Czarnocki²

Address: ¹Forensic Laboratory, Internal Security Agency, 1 Sierpnia 30A, 02-134 Warsaw, Poland, Tel.: +48 693830760 and ²Faculty of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland

Email: Dariusz Błachut - d.blachut@abw.gov.pl

*Corresponding author

**Experimental procedures, spectroscopic and analytical data,
and copies of NMR spectra for representative compounds**

3,5-Dibromo-2,4,6-trimethylpyridine (**1**) [1] and 3-bromo-4-chloro-5-phenyl-2,6-dimethylpyridine (**67**) were prepared according to a previously published procedure [2]. The reagents and solvents were commercially available and were used without further purification. The Suzuki cross coupling reaction was conducted under argon or nitrogen atmosphere in 22 ml vials (Supelco) closed with solid cups sealed with PTFE/silicone septa. TLC analyses were performed on Merck Kiesgel 60 F-254 plates. Visualization of the plates was done under UV light or under iodine vapour. Evaporation of solvents was performed at reduced pressure, using a Büchi rotary evaporator. Melting points were determined on an Electrothermal, Model IA 9200 apparatus and are uncorrected. IR spectra were measured on the Bruker Vortex 70 FTIR spectrometer coupled with Hyperion 2000 microscope. NMR spectra were recorded on a Varian Unity Plus spectrometer operating at 200 MHz for ¹H NMR and 50 MHz for ¹³C NMR or on a Bruker AVANCE 300 MHz spectrometer operating at 300 MHz for ¹H NMR and 75 MHz for ¹³C NMR. The spectra were measured in CDCl₃ and are given as δ values (in ppm) relative to TMS. The following abbreviations are used: m - multiplet, s - singlet, d - doublet, t - triplet, q - quartet. Low resolution mass spectra were collected on a Agilent Technologies 7000 Triple Quad mass detector coupled with a Agilent Technologies 7890A gas chromatograph. The column HP-5MS 30 m × 0.25 mm ID, with 0.25 μm film thickness was operated at flow rate of 1 ml/min (helium) and the oven temperature was ramped between 110– 320 °C. The temperature of the injector port was 250 °C. The mass spectra were recorded in the mass range between 40 and 60 amu. HRMS spectra were collected on Quattro LC Micromass and LCT Micromass TOF HiRes apparatuses.

Cross coupling reaction under Suzuki conditions. General procedure:

Pilot study: A vigorously stirred mixture of **1** (50 mg, 0.18 mmol), phenylboronic acid (61 mg, 0.5 mmol, 2.8 equiv), catalytic system (palladium donor and ligand, for quantity see

Table 1), base (4 equiv., see Table 1) in 2–3 ml of solvent system (see Table 1) was heated (oil bath) under argon atmosphere for appropriate time period. For solvent systems based on toluene/H₂O, toluene, 1,4-dioxane or DMF the temperature was adjusted to 90 °C; toluene/H₂O/EtOH was heated at 85°C. The progress of the reaction and the ratio of products/intermediates were monitored by taking a sample 30–60 µl of organic layer, diluting it with toluene, washing with water (2 ml) and, after drying over anhydrous sodium sulfate, analyzing by GC–MS.

Preparative scale: A vigorously stirred mixture of **1** (150 mg, 0.53 mmol), arylboronic acid (2.8 equiv), palladium acetate (4.0 mol %), S-Phos (8.0 mol %) and K₃PO₄ (4.0 equiv) in 10 ml of toluene was heated at 90 °C (oil bath) under inert gas atmosphere for 1–2 hours. The progress of the reaction was monitored by GC–MS. After completion of the process, the mixture was cooled and quenched with cold water (25 ml). The mixture was then extracted with ethyl acetate (3 × 10 ml). Combined organic extracts were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude mixture was purified by column chromatography on silica gel (230–400 mesh) with the appropriate solvent system. Pure 3,5-diaryl-4-alkoxy-2,4,6-trimethylpyridines **P6 (4–29)** were obtained in moderate to good yield.

3,5-Diphenyl-2,4,6-trimethylpyridine (4)

The general procedure described above was used for the reaction of **1** (150 mg, 0.53 mmol) with phenylboronic acid (180 mg, 1.48 mmol) to afford **4** (141 mg, 96%) as a white solid, mp 188–190 °C.

¹H NMR (200 MHz, CDCl₃): δ = 7.49 – 7.30 (m, 6H), 7.21 – 7.16 (m, 4H), 2.28 (s, 6H), 1.71 (s, 3H)

¹³C NMR (50 MHz, CDCl₃): δ = 154.2, 143.7, 139.8, 134.7, 129.4, 128.9, 127.3, 23.9, 18.6

MS (EI=70eV) m/z (%): 273 (100, M^+), 272 (96), 258 (12), 115 (10), 215 (10), 257 (8), 202 (5), 152 (4);

HRMS (ESI+): m/z calcd for $C_{20}H_{19}NH$ $[M+H]^+$ 274.1596; found 274.1590.

3,5-Bis(2-fluorophenyl)-2,4,6-trimethylpyridine (5)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 2-fluorophenylboronic acid (207 mg, 1.48 mmol) to afford **5** (119 mg, 72%) as a white solid; mp. 162-164 °C.

1H NMR (200 MHz, $CDCl_3$): δ = 7.44 – 7.33 (m, 2H), 7.28 – 7.13 (m, 6H), 2.32 (s, 6H), 1.76 (s, 3H)

^{13}C NMR (50 MHz, $CDCl_3$): δ = 162.3, 157.4, 155.5, 145.2, 131.8, 131.7, 129.9, 129.7, 128.3, 126.8, 126.4, 124.7, 124.6, 116.3, 115.8, 23.6, 18.1

MS (EI=70eV) m/z (%): (309, M^+), 294 (66), 133 (17), 289 (12), 251 (7), 213 (5), 170 (4), 107 (4);

HRMS (ESI+): m/z calcd for $C_{20}H_{17}F_2NH$ $[M+H]^+$ 310.1407; found 310.1401.

3,5-Bis(3-fluorophenyl)-2,4,6-trimethylpyridine (6)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 3-fluorophenylboronic acid (207 mg, 1.48 mmol) to afford **6** (141mg, 85%) as a pale yellow solid; mp 148-149 °C.

1H NMR (200 MHz, $CDCl_3$): δ = 7.48 – 7.37 (m, 2H), 7.13 – 7.03 (m, 2H), 6.98 – 6.88 (m, 4H), 2.29 (s, 6H), 1.72 (s, 3H)

^{13}C NMR (50 MHz, $CDCl_3$): δ = 165.7, 160.8, 154.4, 141.8, 141.7, 133.6, 130.7, 130.5, 125.2, 116.7, 116.3, 114.7, 114.3, 23.9, 18.5

MS (EI=70eV) m/z (%): 308 (100), 309 (98, M^+), 133 (11), 294 (10), 293 (9), 251 (6), 170 (3), 213 (3);

HRMS (ESI+): m/z calcd for $C_{20}H_{17}F_2NH$ $[M+H]^+$ 310.1407; found 310.1410.

3,5-Bis(4-fluorophenyl)-2,4,6-trimethylpyridine (7)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 4-fluorophenylboronic acid (207 mg, 1.48 mmol) to afford **7** (143 mg, 86%) as a yellowish solid; mp 198-200 °C;

1H NMR (200 MHz, $CDCl_3$): δ = 7.16 (bs, 4H), 7.13 (bs, 4H), 2.27 (s, 6H), 1.69 (s, 3H)

^{13}C NMR (50 MHz, $CDCl_3$): δ = 164.7, 159.8, 154.6, 135.5, 135.4, 133.7, 131.1, 130.9, 116.2, 115.8, 23.9, 18.6

MS (EI=70eV) m/z (%) 308 (100), 309 (99, M^+), 133 (12), 291 (10), 251 (9), 155 (5), 213 (4), 279 (4);

HRMS (ESI+): m/z calcd for $C_{20}H_{17}F_2NH$ $[M+H]^+$ 310.1407; found 310.1413.

3,5-Bis(2-methylphenyl)-2,4,6-trimethylpyridine (8)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 2-methylphenylboronic acid (201 mg, 1.48 mmol) to afford **8** (113 mg, 70%) as a white solid; mp 145-146 °C;

1H NMR (300 MHz, $CDCl_3$, two stable atropisomers): δ = 7.33 – 7.23 (m, 6H), 7.10 – 7.02 (m, 2H), 2.22 (2s, 6H), 2.04 (s, 3H), 2.01 (s, 3H), 1.57 (2s, 3H)

^{13}C NMR (75 MHz, $CDCl_3$, two stable atropisomers): δ = 154.1, 154.1, 143.8, 143.7, 139.0, 136.1, 135.9, 133.9, 133.8, 130.4, 129.4, 129.2, 127.7, 126.5, 126.5, 23.4, 23.4, 19.8, 19.7, 17.5

MS (EI=70eV) m/z (%): 301 (100, M^+), 286 (72), 300 (16), 287 (14), 270 (11), 245 (10), 128 (7), 115 (7);

HRMS (ESI+): m/z calcd for $C_{22}H_{23}NH$ $[M+H]^+$ 302.1909; found 302.1915.

3,5-Bis(4-methylphenyl)-2,4,6-trimethylpyridine (9)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 4-methylphenylboronic acid (201 mg, 1.48 mmol) to afford **9** (149 mg, 92%) as a white solid; mp 174-176 °C;

1H NMR (300 MHz, $CDCl_3$): δ = 7.26 – 7.05 (m, 8H), 2.40 (s, 6H), 2.28 (s, 6H), 1.71 (s, 3H)
 ^{13}C NMR (75 MHz, $CDCl_3$): δ = 154.1, 144.0, 136.8, 136.8, 134.6, 129.6, 129.4, 23.9, 21.4, 18.7

MS (EI=70eV) m/z (%): 301 (100, M^+), 300 (69), 286 (13), 229 (6), 115 (5), 270 (4), 202 (3), 151 (3);

HRMS (ESI+): m/z calcd for $C_{22}H_{23}NH$ $[M+H]^+$ 302.1909; found 302.1911.

3,5-Bis(2-methoxyphenyl)-2,4,6-trimethylpyridine (10)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 2-methoxyphenylboronic acid (225 mg, 1.48 mmol) to afford **10** (123 mg, 69%) as a yellowish solid; mp 167-168 °C;

1H NMR (200 MHz, $CDCl_3$): δ = 7.40 – 7.32 (m, 2H), 7.15 – 6.97 (m, 6H), 3.76 (s, 6H), 2.26 (s, 6H), 1.67 (s, 3H)

^{13}C NMR (50 MHz, $CDCl_3$): δ = 156.9, 154.5, 145.1, 131.2, 130.8, 129.0, 128.3, 120.9, 111.1, 55.6, 23.5, 17.9

MS (EI=70eV) m/z (%): 333 (100, M^+), 302 (28), 318 (14), 272 (11), 288 (8), 167 (5), 151 (4), 131 (4);

HRMS (ESI+): m/z calcd for $C_{22}H_{23}O_2NH$ [M+H]⁺ 334.1807; found 334.1812.

3,5-Bis(3-methoxyphenyl)-2,4,6-trimethylpyridine (11)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 3-methoxyphenylboronic acid (225 mg, 1.48 mmol) to afford **11** (152 mg, 85%) as a white solid; mp 141-143 °C;

¹H NMR (200 MHz, CDCl₃): δ = 7.40 – 7.32 (m, 2H), 6.94 – 6.88 (m, 2H), 6.79 – 6.73 (m, 4H), 3.83 (s, 6H), 2.30 (s, 6H), 1.74 (s, 3H)

¹³C NMR (50 MHz, CDCl₃): δ = 160.0, 154.1, 143.6, 141.1, 134.5, 130.0, 121.8, 115.0, 112.7, 55.4, 23.8, 18.5

MS (EI=70eV) *m/z* (%): 333 (100, M⁺), 332 (27), 302 (22), 318 (10), 274 (5), 167 (4), 202 (4), 232 (3);

HRMS (ESI+): m/z calcd for $C_{22}H_{23}O_2NH$ [M+H]⁺ 334.1807; found 334.1816.

3,5-Bis(4-methoxyphenyl)-2,4,6-trimethylpyridine (12)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 4-methoxyphenylboronic acid (225 mg, 1.48 mmol) to afford **12** (143 mg, 80%) as a white solid; mp 182-184 °C;

¹H NMR (200 MHz, CDCl₃): δ = 7.97 – 7.09 (m, 8H), 3.86 (s, 6H), 2.28 (s, 6H), 1.72 (s, 3H)

¹³C NMR (50 MHz, CDCl₃): δ = 158.8, 154.4, 144.6, 134.3, 132.0, 130.5, 114.3, 55.4, 23.9, 18.7

MS (EI=70eV) *m/z* (%): 333 (100, M⁺), 332 (28), 318 (9), 288 (5), 167 (4), 146 (4), 302 (3), 131 (3);

HRMS (ESI+): m/z calcd for $C_{22}H_{23}O_2NH$ [M+H]⁺ 334.1807; found 334.1803.

3,5-Bis(4-ethylphenyl)-2,4,6-trimethylpyridine (13)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 4-ethylphenylboronic acid (222 mg, 1.48 mmol) to afford **13** (159 mg, 90%) as a white solid; mp 120-122 °C;

¹H NMR (300 MHz, CDCl₃): δ = 7.28 – 7.25 (m, 4H), 7.10 – 7.06 (m, 4H), 2.71 (q, *J* = 7.8 Hz, 4H), 2.28 (s, 6H), 1.72 (s, 3H), 1.29 (t, *J* = 7.8 Hz, 6H)

¹³C NMR (75 MHz, CDCl₃): δ = 154.2, 144.0, 143.1, 137.0, 134.7, 129.3, 128.3, 28.8, 23.9, 18.7, 15.6

MS (EI=70eV) *m/z* (%): 329 (100, M⁺), 328 (31), 314 (15), 300 (12), 150 (10), 131 (6), 228 (5) 115 (4);

HRMS (ESI+): m/z calcd for C₂₄H₂₇NH [M+H]⁺ 330.2222; found 330.2228.

3,5-Bis(3-(trifluoromethyl)phenyl)-2,4,6-trimethylpyridine (14)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 3-(trifluorophenyl)boronic acid (403 mg, 2.12 mmol) to afford **14** (110 mg, 50%) as a pale yellow solid; mp 131-133 °C

¹H NMR (300 MHz, CDCl₃): δ = 7.69 – 7.59 (m, 4H), 7.51 – 7.49 (m, 2H), 7.43 – 7.40 (m, 2H), 2.30 (s, 6H), 1.70 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 154.7, 143.5, 140.3, 133.4, 132.92, 132.84, 131.76, 131.71, 131.34, 131.28, 129.61, 129.57, 126.27, 126.21, 126.16, 126.0, 124.5 (q, *J* = 4 Hz, CF₃), 122.4, 23.9, 18.7

MS (EI=70eV) *m/z* (%): 409 (100, M⁺), 408 (90), 394 (7), 338 (6), 393 (6), 283 (4), 215 (4), 115 (3);

HRMS (ESI+): m/z calcd for C₂₂H₁₇F₆NH [M+H]⁺ 410.1343; found 410.1348.

3,5-Bis(4-(trifluoromethyl)phenyl)-2,4,6-trimethylpyridine (15)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 4-(trifluorophenyl)boronic acid (403 mg, 2.12 mmol) to afford **15** (123 mg, 56%) as yellow solid; mp 150-152 °C;

¹H NMR (300 MHz, CDCl₃): δ = 7.75 – 7.72 (m, 4H), 7.35 – 7.32 (m, 4H), 2.28 (s, 6H), 1.68 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 154.5, 143.3, 143.2, 133.5, 129.9, 129.7, 126.1 (q, *J* = 4 Hz, CF₃), 122.5, 23.9, 18.6

MS (EI=70eV) *m/z* (%): 408 (100), 409 (95, M⁺), 394 (8), 393 (7), 338 (7), 283 (5), 115 (4), 215 (3);

HRMS (ESI+): m/z calcd for C₂₂H₁₇F₆NH [M+H]⁺ 410.1343; found 410.1350.

3,5-Bis(2,5-dimethoxyphenyl)-2,4,6-trimethylpyridine (16)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 2,5-dimethoxyphenylboronic acid (386 mg, 2.12 mmol) to afford **16** (95 mg, 45%) as a white solid; mp 173-175 °C;

¹H NMR (200 MHz, CDCl₃): δ = 6.89 – 6.90 (m, 4H), 6.70 – 6.72 (m, 2H), 3.78 (s, 6H), 3.71 (s, 6H), 2.29 (s, 6H), 1.71 (s, 3H)

¹³C NMR (50 MHz, CDCl₃): δ = 154.5, 153.8, 151.2, 145.0, 130.7, 129.2, 117.0, 113.3, 112.1, 56.2, 55.9, 23.4, 17.8

MS (EI=70eV) *m/z* (%): 393 (100, M⁺), 378 (8), 197 (8), 364 (6), 322 (5), 161, (4) 290 (4), 115 (3);

HRMS (ESI+): m/z calcd for C₂₄H₂₇O₄NH [M+H]⁺ 394.2018; found 394.2024.

3,5-Bis(3,4,5-trimethoxyphenyl)-2,4,6-trimethylpyridine (17)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 3,4,5-trimethoxyphenylboronic acid (449 mg, 2.12 mmol) to afford **17** (92 mg, 38%) as a pale brown solid; mp 179-181 °C;

¹H NMR (200 MHz, CDCl₃): δ = 6.39 (s, 4H), 3.92 (s, 6H), 3.85 (s, 12H), 2.33 (s, 6H), 1.82 (s, 3H)

¹³C NMR (50 MHz, CDCl₃): δ = 154.2, 153.5, 143.8, 137.0, 135.0, 134.5, 106.1, 61.0, 56.2, 23.6, 18.3

MS (EI=70eV) *m/z* (%): 438 (100, M⁺), 227 (21), 364 (9), 380 (8), 423 (7), 320 (6) 278 (6), 182 (5);

HRMS (ESI+): *m/z* calcd for C₂₆H₃₁O₆NH [M+H]⁺ 454.2230; found 454.2222.

3,5-Bis(2-ethoxyphenyl)-2,4,6-trimethylpyridine (18)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 2-ethoxyphenylboronic acid (245 mg, 1.48 mmol) to afford **18** (114 mg, 59%) as a white solid; mp 108-110 °C.

¹H NMR (300 MHz, CDCl₃, two stable conformers): δ = 7.35 – 7.29 (m, 2H), 7.10 – 7.07 (m, 2H), 7.03 – 6.95 (m, 4H), 4.08 – 3.89 (m, 4H), 2.28 and 2.27 (2s, 6H), 1.68 and 1.67 (2s, 3H), 1.25 and 1.22 (2t, *J* = 9 Hz, 6H)

¹³C NMR (75 MHz, CDCl₃, two stable conformers): δ = 156.3, 156.2, 154.2, 154.2, 145.1, 131.2, 131.1, 131.0, 131.0, 129.0, 128.8, 128.8, 128.8, 121.0, 120.8, 112.8, 112.2, 64.0, 63.7, 23.5, 23.4, 18.0, 17.8, 15.0, 14.9

MS (EI=70eV) *m/z* (%): 361 (100, M⁺), 288 (16), 345 (15), 332 (13), 328 (13), 304 (112), 372 (11), 202 (5);

HRMS (ESI+): *m/z* calcd for C₂₄H₂₇O₂NH [M+H]⁺ 362.2120; found 362.2127.

3,5-Bis(3-ethoxyphenyl)-2,4,6-trimethylpyridine (19)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 3-ethoxyphenylboronic acid (245 mg, 1.48 mmol) to afford **19** (145 mg, 75%) as a white solid; mp 120-123 °C;

¹H NMR (300 MHz, CDCl₃, two stable atropisomers): δ = 7.37 – 7.31 (m, 2H), 6.91 – 6.87 (m, 2H), 6.76 – 6.71 (m, 4H), 4.05 and 4.04 (2q, *J* = 6 Hz, 4H), 2.30 (s, 6H), 1.74 (s, 3H), 1.42 and 1.43 (2t, *J* = 6 Hz, 6H)

¹³C NMR (75 MHz, CDCl₃, two stable atropisomers): δ = 159.4, 156.1, 154.0, 143.6, 141.1, 134.6, 129.9, 129.9, 122.2, 121.6, 115.5, 113.3, 63.6, 24.3, 23.8, 23.6, 20.3, 18.4, 15.0

MS (EI=70eV) *m/z* (%): 361 (100, M⁺), 332 (10), 304, (8), 316 (6), 260 (5), 153, (5), 232 (4), 202 (3);

HRMS (ESI+): m/z calcd for C₂₄H₂₇O₂NH [M+H]⁺ 362.2120; found 362.2115.

3,5-Bis(4-ethoxyphenyl)-2,4,6-trimethylpyridine (20)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 4-ethoxyphenylboronic acid (245 mg, 1.48 mmol) to afford **20** (155 mg, 80%) as a pale yellow solid; mp 137-138 °C;

¹H NMR (300 MHz, CDCl₃): δ = 7.10 – 7.05 (m, 4H), 6.98 – 6.94 (m, 4H), 4.07 (q, *J* = 7 Hz, 4H), 2.28 (s, 6H), 1.72 (s, 3H), 1.44 (t, *J* = 7 Hz, 6H)

¹³C NMR (75 MHz, CDCl₃): δ = 158.2, 154.4, 144.5, 134.3, 131.6, 130.4, 63.6, 23.9, 18.7, 15.1

MS (EI=70eV) *m/z* (%): 361 (100, M⁺), 304 (13), 332 (10), 131 (7), 274 (5), 202 (3), 248 (3);

HRMS (ESI+): m/z calcd for C₂₄H₂₇O₂NH [M+H]⁺ 362.2120; found 362.2114.

3,5-Bis(3,4-methylenedioxyphenyl)-2,4,6-trimethylpyridine (21)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 3,4-methylenedioxyphenylboronic acid (246 mg, 1.48 mmol) to afford **21** (153 mg, 79%) as a yellow solid; mp 160-162 °C;

¹H NMR (200 MHz, CDCl₃): δ = 6.91 – 6.87 (m, 2H), 6.65 – 6.58 (m, 4H), 6.02 (s, 4H), 2.30 (s, 6H), 1.76 (s, 3H);

¹³C NMR (50 MHz, CDCl₃): δ = 154.5, 148.1, 146.8, 144.5, 134.3, 133.3, 122.6, 109.9, 108.8, 101.3, 23.9, 18.5

MS (EI=70eV) *m/z* (%): 361 (100, M⁺), 302 (9), 181 (8), 330 (7), 151 (7), 101 (5), 228 (4), 204 (3);

HRMS (ESI+): m/z calcd for C₂₂H₁₉O₄NH [M+H]⁺ 362.1392; found 362.1399.

3,5-Bis(2-(methylthio)phenyl)-2,4,6-trimethylpyridine (22)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 2-(methylthio)phenylboronic acid (249 mg, 1.48 mmol) to afford **22** (102 mg, 52%) as pale yellow solid; mp 137-138 °C;

¹H NMR (300 MHz, CDCl₃, two stable atropisomers): δ = 7.39 – 7.33 (m, 2H), 7.27 – 7.18 (m, 4H), 7.11 – 7.04 (m, 2H), 2.38 and 2.37 (2s, 6H), 2.26 (2s, 6H), 1.66 (s, 3H)

¹³C NMR (75 MHz, CDCl₃, two stable atropisomers): δ = 155.2, 155.1, 145.3, 145.2, 138.8, 138.4, 137.4, 137.4, 132.4, 132.3, 129.8, 129.5, 128.3, 125.0, 124.9, 124.5, 124.2, 23.3, 23.3, 17.3, 17.3, 15.2, 15.0

MS (EI=70eV) *m/z* (%) 365 (100, M⁺), 350 (98), 288 (14), 320 (11), 305 (8), 143 (7), 159 (5), 335 (4);

HRMS (ESI+): m/z calcd for C₂₂H₂₃S₂NH [M+H]⁺ 366.1350; found 366.1358.

3,5-Bis(4-(methylthio)phenyl)-2,4,6-trimethylpyridine (23)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 4-(methylthio)phenylboronic acid (249 mg, 1.48 mmol) to afford **23** (127 mg, 65%) as a yellow solid; mp 125-128 °C;

¹H NMR (200 MHz, CDCl₃): δ = 7.36 – 7.31 (m, 4H), 7.13 – 7.07 (m, 4H), 2.54 (s, 6H), 2.28 (s, 6H), 1.72 (s, 3H)

¹³C NMR (50 MHz, CDCl₃): δ = 154.3, 144.1, 137.5, 136.3, 134.1, 129.9, 126.8, 23.9, 18.7, 15.8

MS (EI=70eV) *m/z* (%): 365 (100, M⁺), 183 (8), 332 (7), 317(6), 270 (4), 215 (4), 115 (4), 147 (3);

HRMS (ESI+): m/z calcd for C₂₂H₂₃S₂NH [M+H]⁺ 366.1350; found 366.1357.

3,5-Bis(2-formylphenyl)-2,4,6-trimethylpyridine (24)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 2-formylphenylboronic acid (222 mg, 1.48 mmol) to afford **24** (62 mg, 35%) as a pale brown solid; mp 155-157 °C;

¹H NMR (200 MHz, CDCl₃): δ = 9.83 (s, 2H), 8.09 – 8.05 (m, 2H), 7.77 – 7.69 (m, 2H), 7.62 – 7.54 (m, 2H), 7.29 – 7.25 (m, 2H), 2.26 (s, 6H), 1.61 (s, 3H)

¹³C NMR (50 MHz, CDCl₃): δ = 191.5, 155.2, 144.4, 142.4, 135.0, 133.9, 131.1, 130.7, 128.9, 128.8, 24.0, 18.9

MS (EI=70eV) *m/z* (%): 329 (100, M⁺), 300 (89), 296 (84), 282 (79), 272 (73), 314 (30), 115 (26), 215 (22);

HRMS (ESI+): m/z calcd for C₂₂H₁₉O₂NH [M+H]⁺ 330.1494; found 330.1501.

3,5-Bis(2-cyanophenyl)-2,4,6-trimethylpyridine (25)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 2-cyanophenylboronic acid (217 mg, 1.48 mmol) to afford **25** (73 mg, 42%) as a white solid; mp 201-204 °C;

¹H NMR (300 MHz, CDCl₃): δ = 7.83 – 7.79 (m, 2H), 7.75 – 7.69 (m, 2H), 7.55 – 7.49 (m, 2H), 7.43 – 7.39 (m, 2H), 2.30 (s, 6H), 1.72 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 155.5, 143.9, 143.2, 133.6, 133.4, 131.1, 131.0, 128.5, 117.7, 113.3, 23.6, 18.0

MS (EI=70eV) *m/z* (%): 323 (100, M⁺), 322 (86), 297 (71), 140 (10), 308 (8), 123 (6), 154 (6), 254 (4);

HRMS (ESI+): m/z calcd for C₂₂H₁₇N3H [M+H]⁺ 324.1501; found 324.1506.

3,5-Bis(naphthalen-1-yl)-2,4,6-trimethylpyridine (26)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 1-naphthylphenylboronic acid (254 mg, 1.48 mmol) to afford **26** (160 mg, 80%) as a white solid; mp 226-228 °C;

¹H NMR (300 MHz, CDCl₃, two stable atropisomers): δ = 7.93 – 7.87 (m, 4H), 7.58 – 7.40 (m, 8H), 7.39 – 7.34 (m, 2H), 2.24 (s, 6H), 1.49 (2s, 3H)

¹³C NMR (75 MHz, CDCl₃, two stable atropisomers): δ = 155.5, 155.5, 146.0, 145.9, 137.1, 137.0, 134.0, 134.0, 132.6, 132.5, 131.9, 128.7, 128.7, 128.0, 127.2, 127.1, 126.7, 126.6, 126.2, 125.9, 125.3, 125.1, 23.6, 18.0, 17.9

MS (EI=70eV) *m/z* (%): 373 (100, M⁺), 372 (29), 358 (20), 165 (10), 342 (6), 315 (6), 151 (4), 178 (4);

HRMS (ESI+): m/z calcd for C₂₈H₂₃NH [M+H]⁺ 374.1909; found 3743.1916.

3,5-Bis(naphthalen-2-yl)-2,4,6-trimethylpyridine (27)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 2-naphthylphenylboronic acid (254 mg, 1.48 mmol) to afford **27** (176 mg, 88%) as a white solid; mp 105-107 °C;

¹H NMR (300 MHz, CDCl₃): δ = 7.95 – 7.84 (m, 6H), 7.69 – 7.68 (m, 2H), 7.53 – 7.49 (m, 4H), 7.35 – 7.32 (m, 2H), 2.35 (s, 6H), 1.77 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 154.4, 144.1, 137.2, 134.6, 133.8, 132.6, 128.6, 128.2, 128.1, 128.0, 127.7, 126.5, 126.3, 24.0, 18.9

MS (EI=70eV) *m/z* (%): 373 (100, M⁺), 372 (39), 358 (23), 186 (12), 178 (9), 315 (6), 342 (5), 245 (4);

HRMS (ESI+): m/z calcd for C₂₈H₂₃NH [M+H]⁺ 374.1909; found 374.1913.

3,5-Bis(5'-methoxynaphthalen-2-yl)-2,4,6-trimethylpyridine (28)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 5'-methoxy-2-naphthylphenylboronic acid (299 mg, 1.48 mmol) to afford **28** (195 mg, 84%) as a white solid; mp 196-198 °C;

¹H NMR (300 MHz, CDCl₃): δ = 7.84 – 7.73 (m, 4H), 7.61 – 7.60 (m, 2H), 7.31 – 7.27 (m, 2H), 7.20 – 7.18 (m, 4H), 3.94 (s, 6H), 2.34 (s, 6H), 1.76 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 158.0, 154.4, 144.3, 135.0, 134.6, 133.7, 129.6, 129.2, 128.2, 128.0, 127.4, 119.3, 105.9, 55.6, 24.0, 18.9

MS (EI=70eV) *m/z* (%): 433 (100, M⁺), 217, (18), 418 (8), 389 (6), 152 (6), 253 (5), 346 (4), 152 (3);

HRMS (ESI+): m/z calcd for C₃₀H₂₇O₂NH [M+H]⁺ 434.2120; found 434.2117.

3,5-Bis(2-aminophenyl)-2,4,6-trimethylpyridine (29)

The general procedure described above was applied. Thus, compound **1** (150 mg, 0.53 mmol) was reacted with 2-aminophenylboronic acid hydrochloride (252 mg, 1.48 mmol) to afford **29** (85 mg, 59%) as a yellowish resin;

¹H NMR (300 MHz, CDCl₃): δ = 7.22 – 7.16 (m, 2H), 6.94 – 6.91 (m, 2H), 6.85 – 6.78 (m, 4H), 2.53 (s, 6H), 1.79 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 156.0, 146.8, 143.7, 131.2, 130.1, 128.9, 124.2, 118.9, 115.5, 23.3, 17.2

MS (EI=70eV) *m/z* (%): 303 (100, M⁺), 288 (93), 271 (16), 130 (12), 151 (8), 247 (6), 103 (5), 172 (4);

HRMS (ESI+): *m/z* calcd for C₂₀H₂₁N₃H [M+H]⁺ 304.1814; found 304.1810.

*Monoarylation of **1**:* A vigorously stirred mixture of **1** (300 mg, 1.07 mmol), arylboronic acid (1.1 equiv), PdCl₂(dppf)xCH₂Cl₂ (5.0 mol %), and K₃PO₄ (2.0 equiv) in 15 ml of dioxane was heated at 65 °C (oil bath) under argon atmosphere for 2–4 hours. The reaction was monitored by GC–MS. After cooling to room temperature, the solvent was evaporated under reduced pressure and water (30 ml) was added to the residue. The aqueous solution was extracted with ethyl acetate (2 × 10 ml). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The products were separated and purified by column chromatography.

3-Bromo-5-phenyl-2,4,6-trimethylpyridine (3)

The general procedure described above was applied. Thus, compound **1** (300 mg, 1.07 mmol) was reacted with phenylboronic acid (144 mg, 1.18 mmol) to afford **3** (128 mg, 43%) as a colourless oil;

¹H NMR (300 MHz, CDCl₃): δ = 7.47 – 7.34 (m, 3H), 7.13 – 7.09 (m, 2H), 2.70 (s, 3H), 2.19 (s, 3H), 2.12 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 155.3, 153.8, 145.4, 139.1, 135.9, 129.2, 128.9, 127.7, 122.2, 26.0, 23.5, 21.6

MS (EI=70eV) *m/z* (%): 275 (100, M⁺, ⁷⁹Br), 277 (99, M⁺, ⁸¹Br), 276 (72, ⁸¹Br), 274 (65, ⁷⁹Br), 195 (13), 153 (15), 181 (11), 115 (10);

HRMS (ESI+): *m/z* calcd for C₁₄H₁₅NBrH [M+H]⁺ 276.0388; found 276.0393.

3-Bromo-5-(2-methylphenyl)-2,4,6-trimethylpyridine (43)

The general procedure described above was applied. Thus, compound **1** (300 mg, 1.07 mmol) was reacted with the 2-methylphenylboronic acid (160 mg, 1.18 mmol) to afford **43** (118 mg, 38%) as a colourless oil;

¹H NMR (300 MHz, CDCl₃): δ = 7.31 – 7.27 (m, 2H), 7.27 – 7.22 (m, 1H), 6.99 – 6.96 (m, 1H), 2.71 (s, 3H), 2.12 (s, 3H), 2.06 (s, 3H), 1.98 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 155.4, 153.8, 145.5, 138.4, 135.9, 135.1, 130.5, 129.1, 128.1, 126.6, 122.2, 26.0, 23.0, 21.1, 19.7

MS (EI=70eV) *m/z* (%): 289 (100, M⁺, ⁷⁹Br), 291 (100, M⁺, ⁸¹Br), 195 (79), 274 (45, ⁷⁹Br), 276 (44, ⁸¹Br), 152 (19), 115 (12), 165 (10);

HRMS (ESI+): *m/z* calcd for C₁₅H₁₇NBrH [M+H]⁺ 290.0544; found 290.0538.

3-Bromo-5-(4-methylphenyl)-2,4,6-trimethylpyridine (44)

The general procedure described above was applied. Thus, compound **1** (300 mg, 1.07 mmol) was reacted with 4-methylphenylboronic acid (160 mg, 1.18 mmol) to afford **44** (130 mg, 42%) as a white solid; mp 82-83 °C;

¹H NMR (300 MHz, CDCl₃): δ = 7.27 – 7.22 (m, 2H), 7.01 – 6.97 (m, 2H), 2.69 (s, 3H), 2.41 (s, 3H), 2.19 (s, 3H), 2.12 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 155.2, 154.0, 145.6, 137.3, 136.1, 136.0, 129.6, 129.0, 122.2, 26.0, 23.6, 21.7, 21.4

MS (EI=70eV) *m/z* (%): 289 (100, M⁺, ⁷⁹Br), 291 (100, M⁺, ⁸¹Br), 195 (48), 153 (21), 274 (17, ⁷⁹Br), 276 (16, ⁸¹Br), 115 (11), 128 (8);

HRMS (ESI+): *m/z* calcd for C₁₅H₁₇NBrH [M+H]⁺ 290.0544; found 290.0535.

3-Bromo-5-(naphthalene-2-yl)-2,4,6-trimethylpyridine (45)

The general procedure described above was applied. Thus, compound **1** (300 mg, 1.07 mmol) was reacted with phenylboronic acid (203 mg, 1.18 mmol) to afford **45** (137 mg, 39%) as a pale yellow oil;

¹H NMR (300 MHz, CDCl₃): δ = 7.94 – 7.82 (m, 3H), 7.60 – 7.50 (m, 3H), 7.25 – 7.22 (m, 1H), 2.73 (s, 3H), 2.22 (s, 3H), 2.15 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 155.5, 154.0, 145.7, 136.6, 135.9, 133.6, 132.8, 128.8, 128.2, 128.0, 127.3, 126.7, 126.5, 122.3, 26.1, 23.7, 21.8

MS (EI=70eV) *m/z* (%): 325 (100, M⁺, ⁷⁹Br), 327 (99, M⁺, ⁸¹Br), 326 (51, ⁸¹Br), 324 (39, ⁷⁹Br), 245 (37), 239 (33), 202 (29), 189 (24); 165 (12);

HRMS (ESI+): *m/z* calcd for C₁₈H₁₇NBrH [M+H]⁺ 326.0544; found 326.0550.

Second arylation of **3, **43–45**:** A vigorously stirred mixture of **3** or **43–45**, (arylboronic acid, 1.4 equiv), Pd(OAc)₂ (4 mol %), S-Phos (8 mol %) and K₃PO₄ (3.0 equiv) in toluene was heated at 90 °C (oil bath) under argon atmosphere for 1–4 hours. The reaction was monitored by GC–MS. The mixture was then cooled and quenched with cold water (25–30 ml). The toluene layer was separated and the water layer was additionally extracted with ethyl acetate

(2 × 10 ml). The combined organic extracts were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The products were separated and purified by column chromatography.

3-(2-Methylphenyl)-5-phenyl-2,4,6-trimethylpyridine (46)

The general procedure described above was applied. Thus, compound **3** (70 mg, 0.25 mmol) was reacted with 2-methylphenylboronic acid (43 mg, 0.35 mmol) to afford **46** (64 mg, 88%) as a white solid; mp 117-120 °C;

¹H NMR (300 MHz, CDCl₃): δ = 7.47 – 7.42 (m, 2H), 7.39 – 7.33 (m, 1H), 7.31 – 7.23 (m, 3H), 7.21 – 7.17 (m, 2H), 7.07 – 7.04 (m, 1H), 2.30 (s, 3H), 2.21 (s, 3H), 2.04 (s, 3H), 1.64 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 154.1, 154.1, 143.7, 139.7, 139.0, 136.0, 134.7, 133.8, 130.4, 129.5, 129.4, 129.3, 128.9, 128.8, 127.7, 127.3, 126.5, 23.9, 23.4, 19.8, 18.1
MS (EI=70eV) *m/z* (%): 287 (100, M⁺), 286 (48), 272 (46), 215 (9), 257 (9), 115 (8), 152 (4), 194 (4);

HRMS (ESI+): *m/z* calcd for C₂₁H₂₂NH [M+H]⁺ 288.1752; found 288.1745.

3-(2-(Methylthio)phenyl)-5-phenyl-2,4,6-trimethylpyridine (47)

The general procedure described above was applied. Thus, compound **3** (70 mg, 0.25 mmol) was reacted with 2-(methylthio)phenylboronic acid (58 mg, 0.35 mmol) to afford **47** (62 mg, 85%) as a pale yellow solid; mp 114-116 °C;

¹H NMR (300 MHz, CDCl₃): δ = 7.46 – 7.32 (m, 4H), 7.27 – 7.16 (m, 4H), 7.07 – 7.04 (m, 1H), 2.39 (s, 3H), 2.30 (s, 3H), 2.25 (s, 3H), 1.68 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 154.7, 154.5, 144.6, 139.6, 138.4, 137.3, 134.7, 132.4, 129.6, 129.6, 129.4, 128.8, 128.8, 128.4, 127.3, 125.0, 124.3, 23.9, 23.1, 17.9, 15.0

MS (EI=70eV) m/z (%): 304 (100, M^+), 319 (100), 289 (23), 272 (18), 257 (9), 215 (5), 115 (5), 247 (4);

HRMS (ESI+): m/z calcd for $C_{21}H_{22}SNH$ $[M+H]^+$ 320.1473; found 320.1466.

3-(2-(Trifluoromethyl)phenyl)-5-phenyl-2,4,6-trimethylpyridine (48)

The general procedure described above was applied. Thus, compound **3** (70 mg, 0.25 mmol) was reacted with 2-(trifluoromethyl)phenylboronic acid (66 mg, 0.35 mmol) to afford **48** (58 mg, 68%) as a pale yellow solid; mp 113-115 °C;

1H NMR (300 MHz, $CDCl_3$): δ = 7.82 – 7.79 (m, 1H), 7.66 – 7.60 (m, 1H), 7.54 – 7.33 (m, 4H), 7.25 – 7.15 (m, 3H), 2.30 (s, 3H), 2.19 (s, 3H), 1.62 (s, 3H)

^{13}C NMR (75 MHz, $CDCl_3$): δ = 154.9, 154.1, 144.2, 139.4, 138.5, 134.4, 132.5, 131.6, 131.5, 129.6, 129.2, 129.0, 128.8, 128.0, 127.4, 126.7 (q, J = 5 Hz, CF_3), 125.9, 122.3, 23.9, 23.6, 18.6

MS (EI=70eV) m/z (%): 341 (100, M^+), 340 (78), 272 (33), 326 (7), 115 (6), 215 (5), 181 (3), 241 (3);

HRMS (ESI+): m/z calcd for $C_{21}H_{19}F_3NH$ $[M+H]^+$ 342.1470; found 342.1476.

3-(4-Ethylphenyl)-5-phenyl-2,4,6-trimethylpyridine (49)

The general procedure described above was applied. Thus, compound **3** (70 mg, 0.25 mmol) was reacted with 4-ethylphenylboronic acid (52 mg, 0.35 mmol) to afford **49** (69 mg, 90%) as a white solid; mp 145-148 °C;

1H NMR (300 MHz, $CDCl_3$): δ = 7.467 – 7.40 (m, 2H), 7.37 – 7.31 (m, 1H), 7.28 – 7.24 (m, 2H), 7.19 – 7.16 (m, 2H), 7.11 – 7.07 (m, 2H), 2.70 (q, J = 6Hz, 2H), 2.30 (s, 3H), 2.28 (s, 3H), 1.72 (s, 3H), 1.28 (t, J = 6Hz, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 154.3, 153.9, 143.8, 143.1, 139.8, 136.8, 134.7, 134.6, 129.4, 129.2, 128.8, 128.3, 127.2, 28.7, 23.9, 23.8, 18.6, 15.6

MS (EI=70eV) *m/z* (%): 287 (100, M⁺), 286 (48), 272 (46), 215 (9), 257 (9), 115 (8), 152 (4), 194 (4);

HRMS (ESI+): *m/z* calcd for C₂₂H₂₄NH [M+H]⁺ 302.1909; found 302.1917.

3-(2-(Methylthio)phenyl)-5-(2-methylphenyl)-2,4,6-trimethylpyridine (50)

The general procedure described above was followed when **43** (75 mg, 0.26 mmol) reacted with the 2-(methylthio)phenylboronic acid (60 mg, 0.36 mmol) to afford **50** (71 mg, 88%) as a pale yellow solid; mp 113-114 °C;

¹H NMR (300 MHz, CDCl₃, two stable atropisomers): δ = 7.40 – 7.34 (m, 1H), 7.30 – 7.19 (m, 5H), 7.10 – 7.04 (m, 2H), 2.39 and 2.37 (2s, 3H), 2.26 and 2.25 (2s, 3H), 2.23 and 2.22 (2s, 3H), 2.04 and 2.03 (2s, 3H), 1.62 and 1.61 (2s, 3H)

¹³C NMR (75 MHz, CDCl₃, two stable atropisomers): δ = 154.6, 154.6, 154.6, 154.5, 144.7, 144.5, 139.0, 138.5, 138.5, 137.4, 136.4, 136.0, 133.8, 132.4, 132.3, 130.4, 130.3, 129.6, 129.6, 129.4, 129.1, 128.3, 127.7, 126.4, 126.4, 125.0, 124.3, 124.3, 23.5, 23.4, 23.2, 23.2, 19.8, 19.7, 17.4, 15.0

MS (EI=70eV) *m/z* (%): 318 (100, M⁺), 333 (91), 303 (16), 286 (14), 115 (7), 254 (5), 228 (4), 151 (4);

HRMS (ESI+): *m/z* calcd for C₂₂H₂₄SNH [M+H]⁺ 334.1629; found 334.1621.

3-(3-Fluorophenyl)-5-(2-methylphenyl)-2,4,6-trimethylpyridine (51)

The general procedure described above was followed and **43** (75 mg, 0.26 mmol) was reacted with 3-fluorophenylboronic acid (50 mg, 0.36 mmol) to afford **51** (70 mg, 91%) as a white solid; mp 113-115 °C;

¹H NMR (300 MHz, CDCl₃): δ = 7.45 – 7.38 (m, 1H), 7.33 – 7.24 (m, 3H), 7.10 – 7.03 (m, 2H), 7.00 – 6.90 (m, 2H), 2.30 (s, 3H), 2.21 (s, 3H), 2.03 (2s, 3H), 1.65 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 164.80, 161.52, 154.58, 153.87, 143.55, 141.97, 141.87, 138.77, 136.01, 135.95, 133.86, 133.54, 133.51, 130.54, 130.51, 130.45, 130.43, 129.26, 129.23, 127.80, 126.55, 126.52, 125.31, 125.27, 125.25, 125.22, 116.66, 116.62, 116.38, 116.34, 114.47, 114.19, 23.79, 23.40, 19.75, 17.97

MS (EI=70eV) *m/z* (%): 305 (100, M⁺), 304 (53), 290 (52), 275 (8), 233 (8), 115 (6), 152 (5), 194 (3);

HRMS (ESI+): *m/z* calcd for C₂₁H₂₁FNH [M+H]⁺ 306.1658; found 306.1650.

3-(2-(trifluoromethyl)phenyl)-5-(4-methylphenyl)-2,4,6-trimethylpyridine 52

The general procedure described above was followed and **44** (80 mg, 0.27 mmol) was reacted with 2-(trifluoromethyl)phenylboronic acid (72 mg, 0.38 mmol) to afford **52** (61 mg, 62%) as a pale yellow oil;

¹H NMR (300 MHz, CDCl₃): δ = 7.81 – 7.78 (m, 1H), 7.65 – 7.60 (m, 1H), 7.53 – 7.47 (m, 1H), 7.26 – 7.22 (m, 3H), 7.08 – 7.04 (m, 2H), 2.40 (s, 3H), 2.30 (s, 3H), 2.19 (s, 3H), 1.62 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 155.1, 153.9, 144.3, 138.6, 137.0, 136.3, 134.4, 132.4, 131.6, 131.5, 129.6, 129.5, 129.4, 129.1, 127.9, 126.7 (q, *J* = 5 Hz, CF₃), 125.9, 122.3, 23.9, 23.6, 21.4, 18.6

MS (EI=70eV) *m/z* (%): 355 (100, M⁺), 354 (37), 286 (23), 115 (5), 228 (4), 128 (4), 254 (3), 178 (3);

HRMS (ESI+): *m/z* calcd for C₂₂H₂₁F₃NH [M+H]⁺ 356.1626; found 356.1634.

3-(2-(Methylthio)phenyl)-5-(4-methylphenyl)-2,4,6-trimethylpyridine (53)

The general procedure described above was followed when **44** (80 mg, 0.27 mmol) reacted with the 2-(methylthio)phenylboronic acid (64 mg, 0.38 mmol) to afford **53** (83 mg, 90%) as a pale yellow oil;

¹H NMR (300 MHz, CDCl₃): δ = 7.39 – 7.34 (m, 1H), 7.26 – 7.18 (m, 4H), 7.12 – 7.04 (m, 3H), 2.40 (s, 3H), 2.38 (s, 3H), 2.30 (s, 3H), 2.24 (s, 3H), 1.68 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 154.9, 154.3, 144.6, 138.4, 137.5, 136.8, 136.6, 134.6, 132.3, 129.6, 129.5, 129.5, 129.2, 128.3, 125.0, 124.3, 24.0, 23.2, 21.4, 17.9, 15.0

MS (EI=70eV) *m/z* (%): 318 (100, M⁺), 333 (97), 303 (30), 286 (22), 128 (6), 228 (5), 151 (4), 202 (3);

HRMS (ESI+): *m/z* calcd for C₂₂H₂₄SNH [M+H]⁺ 334.1629; found 334.1637.

3-(2-Methylphenyl)-5-(4-methylphenyl)-2,4,6-trimethylpyridine (54)

The general procedure described above was followed when **44** (80 mg, 0.27 mmol) reacted with the 2-methylphenylboronic acid (52 mg, 0.38 mmol) to afford **54** (73 mg, 88%) as a white solid: mp 94-96 °C;

¹H NMR (300 MHz, CDCl₃): δ = 7.32 – 7.22 (m, 5H), 7.09 – 7.03 (m, 3H), 2.41 (s, 3H), 2.30 (s, 3H), 2.20 (s, 3H), 2.03 (s, 3H), 1.64 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 154.3, 153.9, 143.9, 139.1, 136.9, 136.7, 136.1, 134.7, 133.8, 130.4, 129.6, 129.5, 129.3, 129.3, 127.7, 126.5, 23.9, 23.4, 21.4, 19.8, 18.1

MS (EI=70eV) *m/z* (%): 301 (100, M⁺), 286 (36), 300 (31), 270 (5), 229 (4), 115 (4), 202 (3), 152 (3);

HRMS (ESI+): *m/z* calcd for C₂₂H₂₄NH [M+H]⁺ 302.1909; found 302.1916.

3-(2-Methylphenyl)-5-(naphthyl-2-yl)-2,4,6-trimethylpyridine (55)

The general procedure described above was followed when **45** (75 mg, 0.23 mmol) reacted with the 2-methylphenylboronic acid (43 mg, 0.32 mmol) to afford **55** (63 mg, 82%) as a pale yellow oil;

¹H NMR (300 MHz, CDCl₃): δ = 7.94 – 7.84 (m, 3H), 7.67 (s, 1H), 7.54 – 7.48 (m, 2H), 7.33 – 7.24 (m, 4H), 7.10 – 7.06 (m, 1H), 2.33 (s, 3H), 2.24 (s, 3H), 2.07 and 2.06 (2s, 3H), 1.67 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 154.2, 154.2, 143.9, 139.0, 137.2, 137.2, 136.0, 136.0, 134.6, 133.9, 133.7, 132.6, 130.4, 129.3, 128.6, 128.6, 128.2, 128.1, 128.1, 128.0, 127.7, 127.7, 126.5, 126.5, 126.2, 24.0, 23.4, 19.8, 19.8, 18.2, 18.2

MS (EI=70eV) *m/z* (%): 337 (100, M⁺), 336 (35), 322 (29), 165 (7), 265 (5), 115 (4), 139 (3), 202 (3);

HRMS (ESI+): *m/z* calcd for C₂₅H₂₄NH [M+H]⁺ 338.1909; found 338.1900.

3-(3-Fluorophenyl)-5-(naphthyl-2-yl)-2,4,6-trimethylpyridine (56)

The general procedure described above was followed when **45** (75 mg, 0.23 mmol) reacted with the 3-fluorophenylboronic acid (45 mg, 0.32 mmol) to afford **56** (71 mg, 90%) as a yellow oil;

¹H NMR (300 MHz, CDCl₃): δ = 7.94 – 7.83 (m, 3H), 7.66(br s, 1H), 7.54 – 7.48 (m, 2H), 7.45 – 7.37 (m, 1H), 7.32 – 7.28 (m, 1H), 7.10 – 7.03 (m, 1H), 7.01 – 6.92 (m, 2H), 2.32 (2s, 6H), 1.74 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 164.8, 161.5, 154.8, 154.0, 143.7, 142.0, 141.9, 137.0, 134.6, 133.7, 133.5, 133.5, 132.6, 130.6, 130.5, 128.7, 128.6, 128.2, 128.1, 128.1, 128.0, 128.0, 127.6, 127.5, 126.5, 126.3, 125.2, 125.2, 116.6, 116.3, 114.5, 114.2, 24.0, 23.8, 18.6

MS (EI=70eV) m/z (%): 341 (100, M^+), 340 (56), 326 (22), 283 (6), 165 (5), 133 (4), 246 (3), 311 (3);

HRMS (ESI+): m/z calcd for $C_{24}H_{21}FNH$ $[M+H]^+$ 342.1658; found 342.1665.

Arylation of 67: A vigorously stirred mixture of **67** (1 equiv), arylboronic acid (1.3 equiv), $Pd(OAc)_2$ (5 mol %), S-Phos (10 mol %) and K_3PO_4 (3.0 equiv) in toluene (8 ml) was heated at 90 °C (oil bath) under argon atmosphere for 1–3 hours. The reaction was monitored by GC–MS. The mixture was then cooled and quenched with cold water (20 ml). The toluene layer was separated and water layer was additionally extracted with ethyl acetate (2×5 ml). The combined organic solutions were dried over anhydrous sodium sulphate and concentrated under reduced pressure. The products were separated and purified by column chromatography.

4-Chloro-3-(2-methylphenyl)-5-phenyl-2,6-dimethylpyridine (68)

The general procedure described above was followed when **67** (85 mg, 0.29 mmol) reacted with the 2-methylphenylboronic acid (55 mg, 0.38 mmol) to afford **68** (65 mg, 74%) as a white solid; mp 141–142 °C;

1H NMR (300 MHz, $CDCl_3$): δ = 7.49 – 7.37 (m, 3H), 7.33 – 7.23 (m, 5H), 7.11 – 7.08 (m, 1H), 2.36 (s, 3H), 2.26 (s, 3H), 2.09 (s, 3H)

^{13}C NMR (75 MHz, $CDCl_3$): δ = 156.2, 143.2, 137.6, 137.2, 136.3, 133.5, 132.9, 130.4, 129.6, 129.6, 129.3, 128.8, 128.7, 128.4, 128.0, 126.4, 24.2, 23.7, 19.7

MS (EI=70eV) m/z (%): 307 (100, M^+ , ^{35}Cl), 309 (32, M^+ , ^{37}Cl), 292 (30), 215 (17), 272 (12), 115 (8), 152 (5), 181 (5);

HRMS (ESI+): m/z calcd for $C_{20}H_{19}NClH$ $[M+H]^+$ 308.1206; found 308.1212.

4-Chloro-3-(2-(methylthio)phenyl)-5-phenyl-2,6-dimethylpyridine (69)

The general procedure described above was followed when **67** (85 mg, 0.29 mmol) reacted with the 2-(methylthio)phenylboronic acid (64 mg, 0.38 mmol) to afford **69** (63 mg, 67%) as a pale pink oil;

¹H NMR (300 MHz, CDCl₃): δ = 7.48 – 7.36 (m, 4H), 7.32 – 7.22 (m, 4H), 7.12 – 7.09 (m, 1H), 2.41 (s, 3H), 2.36 (s, 3H), 2.30 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 156.7, 143.6, 138.4, 137.5, 136.0, 133.5, 131.6, 129.8, 129.7, 129.5, 129.0, 128.7, 128.7, 128.0, 125.2, 24.2, 23.5, 15.5

MS (EI=70eV) *m/z* (%): 304 (100, M⁺), 309 (32,), 273 (8), 247 (7), 215 (7), 339 (5, M⁺, ³⁵Cl), 137 (4), 162 (3);

HRMS (ESI+): m/z calcd for C₂₀H₁₉SNClH [M+H]⁺ 340.0927; found 340.0934.

4-Chloro-3-(2-(trifluoromethyl)phenyl)-5-phenyl-2,6-dimethylpyridine (70)

The general procedure described above was followed when **67** (85 mg, 0.29 mmol) reacted with the 2-(trifluoromethyl)phenylboronic acid (72 mg, 0.38 mmol) to afford **70** (67 mg, 65%) as a white solid; mp 117-119 °C;

¹H NMR (300 MHz, CDCl₃): δ = 7.83 – 7.80 (m, 1H), 7.68 – 7.62 (m, 1H), 7.58 – 7.52 (m, 1H), 7.50 – 7.37 (m, 3H), 7.28 – 7.21 (m, 3H), 2.36 (s, 3H), 2.25 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 157.0, 156.1, 143.5, 137.3, 136.3, 133.3, 132.5, 131.5, 130.8, 129.8, 129.4, 128.9, 128.7, 128.6, 128.1, 126.8 (q, *J* = 5 Hz, CF₃), 24.2, 23.8

MS (EI=70eV) *m/z* (%): 361 (100, M⁺), 360 (67,), 273 (8), 292 (24), 215 (10), 326 (8), 115 (5), 142 (4);

HRMS (ESI+): m/z calcd for C₂₀H₁₆F₃NClH [M+H]⁺ 362.0923; found 362.0933.

4-Chloro-3-(naphthalen-1-yl)-5-phenyl-2,6-dimethylpyridine (71)

The general procedure described above was followed when **67** (85 mg, 0.29 mmol) reacted with the 1-naphthylboronic acid (65 mg, 0.38 mmol) to afford **71** (25 mg, 25%) as a yellow solid; mp 158-160°.

¹H NMR (300 MHz, CDCl₃): δ = 7.94 – 7.90 (m, 2H), 7.59 – 7.25 (m, 10H), 2.42 (s, 3H), 2.22 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 157.1, 156.6, 144.0, 137.5, 135.2, 133.9, 133.6, 131.7, 131.6, 129.7, 129.6, 128.8, 128.7, 128.6, 128.0, 127.4, 126.8, 126.3, 125.8, 125.0, 24.3, 23.8
MS (EI=70eV) *m/z* (%): 361 (100, M⁺), 360 (67), 273 (8), 292 (24), 215 (10), 326 (8), 115 (5), 142 (4);

HRMS (ESI+): m/z calcd for C₂₃H₁₉NClH [M+H]⁺ 344.1206; found 344.1214.

Also, the following compound was isolated from the reaction mixture as main compound:

3,4-Bis(naphthalen-1-yl)-5-phenyl-2,6-dimethylpyridine (72) as a pale yellow solid (61 mg, 49 %).

¹H NMR (300 MHz, CDCl₃): δ = 7.70 – 7.58 (m, 3H), 7.49 – 7.43 (m, 4H), 7.41 – 7.20 (m, 4H), 7.0 – 6.93 (m, 3H), 6.91 – 6.86 (m, 3H), 6.76 – 6.68 (m, 2H), 2.50 (s, 3H), 2.26 (s, 3H)

¹³C NMR (75 MHz, CDCl₃): δ = 156.0, 155.3, 148.3, 138.5, 136.2, 135.9, 134.8, 133.3, 132.6, 132.5, 132.2, 131.6, 130.1, 129.2, 128.4, 127.9, 127.5, 127.4, 127.2, 126.7, 126.6, 126.5, 126.4, 126.2, 125.8, 125.7, 125.4, 125.3, 125.0, 124.1, 24.2, 23.6

MS (EI=70eV) *m/z* (%): 435 (100, M⁺), 420 (12), 276 (9), 188 (6), 376 (6), 342 (4), 313 (3), 115 (3);

HRMS (ESI+): m/z calcd for C₃₃H₂₆NH [M+H]⁺ 436.2065; found 436.2065.

Some products were tentatively identified on the basis of their mass spectra. Most of compounds exhibited characteristic mass spectra with major or at least highly abundant peak corresponding to the molecular ion.

Compound listed in Table 2 (article text):

3-(4-Fluorophenyl)-5-phenyl-2,4,6-trimethylpyridine (57) (entry 3 and 4):

MS (EI=70eV) m/z (%): 291 (100, M^+), 290 (95), 275 (10), 276 (9), 233 (7), 133 (5), 170 (4), 213 (2).

3-(4-Methoxyphenyl)-5-phenyl-2,4,6-trimethylpyridine (58) (entry 5 and 6):

MS (EI=70eV) m/z (%): 303 (100, M^+), 302 (45), 288 (12), 258 (8), 272 (6), 244 (5), 146 (4), 131 (4).

3-(4-(Trifluoromethyl)phenyl)-5-phenyl-2,4,6-trimethylpyridine (59) (entry 7 and 8):

MS (EI=70eV) m/z (%): 341 (100, M^+), 340 (97), 115 (15), 326 (13), 215 (10), 325 (9), 337 (4), 283 (3).

3-(3,4-Methylenedioxophenyl)-5-phenyl-2,4,6-trimethylpyridine (60) (entry 9 and 10):

MS (EI=70eV) m/z (%): 317 (100, M^+), 316 (38), 258 (11), 286 (7), 202 (5), 286 (5), 101 (4), 228 (4).

3-(2-Methoxyphenyl)-5-phenyl-2,4,6-trimethylpyridine (61) (entry 13 and 14):

MS (EI=70eV) m/z (%): 303 (100, M^+), 302 (32), 272 (30), 283 (15), 115 (8), 215 (7), 151 (4), 131 (3).

3,5-Bis(2-(trifluoromethyl)phenyl)-2,4,6-trimethylpyridine (31) (entry 15, Ar_2/Ar_2 pyridine):

MS (EI=70eV) m/z (%): 409 (78, M^+), 340 (100), 164 (5), 133 (5), 195 (4), 183 (3), 394 (3), 226 (3).

3-(2-Methoxyphenyl)-5-(4-methoxyphenyl)-2,4,6-trimethylpyridine (62) (17 and 18):

MS (EI=70eV) m/z (%): 333 (100, M^{+}), 332 (15), 302 (11), 318 (9), 131 (5), 288 (5), 272 (3), 146 (3).

3-(4-Fluorophenyl)-5-(4-methoxyphenyl)-2,4,6-trimethylpyridine (63) (entry 19 and 20):

MS (EI=70eV) m/z (%): 321 (100, M^{+}), 320 (44), 306 (11), 276 (8), 262 (7), 290 (7), 170 (5), 146 (3).

3-(3,4-Methylenedioxyphenyl)-5-(4-(trifluoromethyl)phenyl)-2,4,6-trimethylpyridine (64) (entry 21 and 22):

MS (EI=70eV) m/z (%): 385 (100, M^{+}), 384 (28), 326 (11), 354 (6), 366 (6), 312 (5), 228 (3), 102 (3).

3,5-Bis(2-chlorophenyl)-2,4,6-trimethylpyridine (30) (entry 23 and 24, Ar_1/Ar_1 pyridine):

MS (EI=70eV) m/z (%): 307 (100, ^{35}Cl), 342 (36, M^{+} , ^{35}Cl , ^{35}Cl), 309 (35, ^{37}Cl), 344 (26, ^{37}Cl , ^{37}Cl), 256 (7), 128 (6), 271 (5), 136 (4).

3-(2-Methylphenyl)-5-(2-(trifluoromethyl)phenyl)-2,4,6-trimethylpyridine (66) (entry 25 and 26, Ar_1/Ar_2 pyridine):

MS (EI=70eV) m/z (%): 355 (100, M^{+}), 340 (61), 286 (32), 325 (8), 115 (6), 128 (5), 270 (4), 299 (4).

3-(2-(Trifluoromethyl)phenyl)-2,4,6-trimethylpyridine (entry 25 and 26, monoaryl pyridine):

MS (EI=70eV) m/z (%): 265 (100, M^{+}), 196 (84), 195 (15), 181 (13), 164 (8), 133 (7), 226 (4), 183 (3).

3-(2-Methylphenyl)-2,4,6-trimethylpyridine (entry 25 and 26, monoaryl pyridine):


MS (EI=70eV) m/z (%): 211 (100, M^{+}), 196 (88), 210 (14), 195 (13), 181 (13), 128 (11), 127 (7), 115 (4).


3-Bromo-5-(2-(trifluoromethyl)phenyl)-2,4,6-trimethylpyridine (entry 23 and 24, monoaryl bromopyridine):


MS (EI=70eV) m/z (%): 345 (100, M^+ ; ^{81}Br), 343 (99, M^+ ; ^{79}Br), 274 (46), 276 (42), 195 (12), 183 (9).

References

- [1] Drzeniek, W., Tomasik, P., *Roczniki Chemii* **1970**, *44*, 779 - 783.
- [2] D. Błachut, Z. Czarnocki, K. Wojtasiewicz, *Synthesis* **2006**, *17*, 2855-2864










27754-13C
27754-13C


DB-2F



594.1.fid
594-1H
Pirydyna sym diAr 2-CH3 f2





594.2.fid
594-13C
Pirydyna sym diAr 2-CH3 f2




565.1.fid

565-1H



pirydyna sym diAr 4-Me




565.2.fid
565-13C
pirydyna sym diAr 4-Me





506.1.fid
506-1H
sym diAr 4-Et



506.2.fid
506-13C
sym diAr 4-Et



505.1.fid
505-1H
sym diAr 4-CF₃




505.2.fid
505-13C
sym diAr 4-CF3

— 154.53



143.29
143.18
133.50
130.13
129.87
129.69
126.11
126.06
126.01
125.96
122.53

77.64
77.22
76.80


— 23.94
— 18.59



309.1.fid
309-1H
DB/JJS-17 KW-Ra






309.2.fid
309-13C
DB/JJS-17 KW-Ra





28335-1H
28335-1H

DB-3,4O2CH2








5751.1.fid
5751-1H
DB/JJS-22C




5751.2.fid
5751-13C
DB/JJS-22C



50192-1H
50192-1H
DB/JJS-14








4702.1.fid

4702-1H


JJS/DB sym triCH3 3,5-di-1-Nafty




4702.2.fid
4702-13C
JJS/DB sym triCH3 3,5-di-1-Nafty



176.1.fid
176-1H
DB/JJS-16B



27




176.2.fid
176-13C
DB/JJS-16B

— 154.41


— 144.08
— 137.20
— 134.61
— 133.74
— 132.63
— 128.62
— 128.19
— 128.09
— 127.98
— 127.67
— 126.49
— 126.24





— 77.65
— 77.43
— 77.22
— 76.80

— 24.02
— 18.87




6416.1.fid
6416-1H
DB/JJS - 23 B








6416.2.fid
6416-13C
DB/JJS - 23 B





6539.1.fid
6539-1H
DB/JJS-23C f1




6539.2.fid
6539-13C
DB/JJS-23C f1




1577.1.fid
1577-1H
sym diAr (4-H + 4-Et)




1577.2.fid
1577-13C
sym diAr (4-H + 4-Et)




6588.1.fid
6588-1H
DB/JJS-25D




50




6588.2.fid
6588-13C
DB/JJS-25D




6542.1.fid
6542-1H
DB/JJS-25C




51




6542.2.fid
6542-13C
DB/JJS-25C





6587.1.fid
6587-1H
DB/JJS-24B




6587.2.fid
6587-13C
DB/JJS-24B




5549.1.fid
5549-1H
DB/JJS-20C




5549.2.fid
5549-13C
DB/JJS-20C




5547.1.fid
5547-1H
DB/JJS-20A




45




5547.2.fid
5547-13C
DB/JJS-20A




6658.1.fid
6658-1H
DB/JJS-26 B





68







6658.2.fid
6658-13C
DB/JJS-26 B



6657.1.fid
6657-1H
DB/JJS-26 A





6657.2.fid
6657-13C
DB/JJS-26 A

